This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?
The U.S. regulatory authority wants to switch to 'more effective, human-relevant methods' instead, including machine learning and artificial intelligence, according to its press release on Friday.
FDA's announcement is driving RXRX higher as it aligns perfectly with Recursion Pharmaceuticals' core business. The biotechnology company specializes in using AI for accelerated drug discovery.
Despite today's surge, however, Recursion Pharmaceuticals stock is down nearly 55% versus its year-to-date high.
Is It Too Late to Invest in Recursion Pharmaceuticals?
FDA's announcement could help Recursion Pharmaceuticals push further to the upside as it has a massive dataset of more than 60 petabytes, which is one of the largest in the biotech space.
Recursion already counts notable names like Roche (RHHBY), Merck (MRK), and Sanofi (SNY) as partners.
And with FDA promoting the use of AI models in drug development, it's reasonable to believe that other drugmakers would want to follow suit, potentially helping RXRX shares extend gains through the remainder of 2025.
In fact, the biotech stock could climb all the way back to $11 by the end of this year, according to Gil Blum – a senior analyst at Needham.
Why Is Needham Bullish on RXRX Shares?
Recursion Pharmaceuticals came in shy of Street estimates in its latest reported quarter in February.
Still, Blum expects RXRX to nearly double from current levels as it has a promising pipeline. It's REC-617, for example, has shown encouraging results in early clinical studies.
Recursion stock will extend gains as the biotechnology company continues to advance its clinical programs and capitalize on strategic partnerships to foster innovation in 2025, he added.
Needham expects Recursion to achieve significant synergies from its $688 million Exscientia deal as well.
What's the Consensus Rating on Recursion Stock?
Other Wall Street analysts are not as bullish on Recursion Pharmaceuticals as Needham, given the consensus rating on RXRX currently sits at 'Hold.'
However, their mean target of $8.50 still represents potential upside of more than 50% from here.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 days ago
- Globe and Mail
Abbott Taps Growing TMVR Market With Tendyne System
Abbott Laboratories ABT recently received Food and Drug Administration ('FDA') approval for its Tendyne transcatheter mitral valve replacement (TMVR) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (MAC). The Tendyne system expands the company's comprehensive Structural Heart portfolio. The rising prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population has driven the adoption of TMVR system. Investors are eyeing this fast-growing market, which is projected to witness a compound annual growth rate of 20% from 2025 to 2030 (Per a Medi-Tech Insights report). MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery. The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement. Offerings By ABT's Peers in the Structural Heart Field Edwards Lifesciences EW makes significant investments in the development of transcatheter heart valve repair and replacement technologies designed to treat mitral and tricuspid valve diseases. The company's PASCAL Precision system addresses the needs of patients with mitral or tricuspid regurgitation through leaflet approximation. The EVOQUE system is the world's first transcatheter tricuspid valve replacement therapy to receive regulatory approval. It addresses tricuspid valve regurgitation by replacing the native valve with a bioprosthetic valve. In addition, SAPIEN M3 transcatheter mitral valve replacement system is designed specifically for patients with symptomatic mitral regurgitation. Medtronic 's MDT Structural Heart & Aortic division offers therapies for heart valve disorders and aortic disease. Key products include the CoreValve family (Evolut PRO, PRO+, FX, FX+ TAVR systems), surgical valve replacement and repair solutions (tissue and mechanical), blood-handling systems, surgical ablation technologies, and positioning/stabilization tools. The company also provides endovascular stent grafts and accessories like the Endurant II Stent Graft System (abdominal aortic aneurysms), Valiant Captivia Thoracic Stent Graft System (thoracic repair) and Heli-FX EndoAnchor System. ABT Price Performance In the past year, Abbott shares have surged 19.2%, outperforming the industry's 6.2% growth. The S&P 500 composite grew 17.8% in the same period. Image Source: Zacks Investment Research Discounted Valuation ABT currently trades at a forward 12-month Price-to-Sales (P/S) of 4.87X compared with the industry average of 5.56X. Image Source: Zacks Investment Research ABT Stock Estimate Trend In the past 30 days, Tempus AI's EPS estimate has moved south 0.2% for 2025. Image Source: Zacks Investment Research ABT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report Medtronic PLC (MDT): Free Stock Analysis Report Edwards Lifesciences Corporation (EW): Free Stock Analysis Report This article originally published on Zacks Investment Research (
The Market Online
4 days ago
- The Market Online
MediPharm lays out the implications for possible new U.S. cannabis rescheduling
MediPharm Labs states it is positioned for potential U.S. cannabis rescheduling, having completed FDA site registration and filed a Drug Master File for CBD API Rescheduling cannabis to Schedule III would enable expanded medical research and access programs in the U.S., similar to those in Canada, Australia, and Germany The company will release its Q2 2025 financial results before markets open on Thursday, August 14, 2025, continuing its commitment to transparency and growth MediPharm Labs stock (TSX:LABS) last traded at $0.07 MediPharm Labs (TSX:LABS) shared its insights into its U.S. FDA site registration and strategic readiness in light of the potential federal rescheduling of cannabis in the United States. This content has been prepared as part of a partnership with MediPharm Labs Corp. and is intended for informational purposes only. Recent communications from the U.S. federal government and widespread media coverage suggest that the administration is actively reviewing the reclassification of cannabis from a Schedule I to a Schedule III controlled substance. This shift would mark a significant milestone in federal cannabis policy, recognizing its medical benefits and unlocking new pathways for research and patient access. Implications of rescheduling cannabis If cannabis is reclassified as a Schedule III drug: It would formally acknowledge its medical utility at the federal level Researchers in the U.S. would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers currently imposed by Schedule I classification The move could pave the way for expanded medical cannabis programs similar to those in Canada, Australia, and Germany Cannabis businesses would benefit from tax relief under Section 280E, which currently penalizes Schedule I and II substance handlers MediPharm's unique positioning MediPharm Labs stands out as one of the few companies globally—and the only publicly listed cannabis-focused firm in North America—with a comprehensive suite of regulatory approvals and infrastructure to capitalize on this potential shift: The company has successfully completed the process of foreign drug manufacturing site registration with the U.S. FDA, including a week-long inspection that granted it the authority to produce, label, test, and release pharmaceutical-grade cannabis products MediPharm has filed a Drug Master File with the FDA for its CBD active pharmaceutical ingredient (API), an important step for enabling late-stage clinical trials and finished dose product development It has already shipped cannabis API and products to the U.S. for research purposes, including a National Institutes of Health-funded clinical trial—an achievement made possible through FDA registration and DEA-issued import permits With these credentials, MediPharm sees itself in a stable position to support the anticipated surge in U.S.-based cannabis research and potential new medical access programs. The company's purpose-built, FDA-audited facility in Canada is one of only a handful worldwide capable of meeting the stringent standards required for pharmaceutical cannabis production. MediPharm Labs continues to uphold its pharmaceutical licenses and remains committed to serving researchers and patients with its brew of cannabinoid products. The company continues to watch developments in U.S. cannabis policy, ready to expand its footprint in the American market. The company plans to release its Q2 financial results for the three and six months ended June 30, 2025, before markets open on Thursday, August 14, 2025. MediPharm develops and manufactures pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients and advanced derivative products. MediPharm Labs stock (TSX:LABS) last traded at $0.07. Though up 25.00 per cent since the year began, the stock has also climbed 7.14 per cent since this time last year. Join the discussion: Find out what the Bullboards are saying about MediPharm Labs and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Globe and Mail
5 days ago
- Globe and Mail
Psychedelic Pharma Stock Surges on FDA Breakthrough
The psychedelic pharmaceutical sector continues gaining mainstream acceptance as regulatory barriers fall and medical applications expand beyond traditional treatments. With mental health disorders reaching epidemic proportions and conventional therapies showing limited efficacy for many patients, regulators are increasingly open to alternative treatments that were once considered fringe. This paradigm shift has created significant opportunities for companies positioned at the intersection of established pharmaceutical development and emerging psychedelic therapeutics. Shares of PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) are moving higher in Monday afternoon trading following the announcement that the company received FDA approval for its ketamine product, KETARx™, on August 8th for surgical pain management applications. This milestone represents a significant breakthrough for the specialty pharmaceutical company focused on unlocking ketamine's therapeutic potential across multiple medical conditions. The FDA approval positions PharmaTher to capitalize on the rapidly expanding ketamine market, which is currently valued at $750 million and projected to reach $3.42 billion by 2034, representing a compound annual growth rate of 16.4%. Ketamine stands out among psychedelic compounds as the only one included on the World Health Organization's Model List of Essential Medicines, providing additional validation for its therapeutic applications. The approval comes at an opportune time, as ketamine has been regularly listed on the FDA drug shortage list since February 2018, highlighting significant supply challenges in the market. The FDA has also issued compounding risk alerts regarding potential safety issues with non-approved ketamine products, creating demand for high-quality, FDA-approved alternatives like KETARx™. PharmaTher's FDA approval provides a strong foundation for expanding ketamine development across diverse therapeutic areas within the company's pipeline, including mental health conditions like depression, neurological disorders such as Parkinson's disease and ALS, and chronic pain management including Complex Regional Pain Syndrome. The market potential is demonstrated by SPRAVATO (esketamine), an FDA-approved depression treatment currently tracking a $1.6 billion sales run rate with guidance projecting $3 billion to $3.5 billion by 2027-2028. Additionally, the Veterans Health Administration currently approves and funds ketamine infusions for retired military personnel with depression, PTSD, and chronic pain, indicating established institutional acceptance. "Today marks a new chapter for PharmaTher," commented CEO Fabio Chianelli. "With FDA approval for ketamine now in hand, we are closer to realizing our goal of becoming a global leader in ketamine-based pharmaceuticals. This historic FDA approval for PharmaTher is a testament to years of dedicated development, signaling a new era of growth." U.S. shares of PHRRF are up 8.6% at $0.39, while Canadian shares of PHRM are ahead 8.0% at C$0.54 in Monday afternoon trading. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
